Arabic Arabic English English French French German German
dark

Spanish pharmaceutical company Zendal and IAVI partner to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials

Biofabri and IAVI today announced their intention to partner on efficacy trials of the tuberculosis (TB) vaccine candidate MTBVAC. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

COVID Vaccine’s 2nd Dose Boosts Body Immunity, MOH Says

Next Post

Avacta’s Diagnostic Division Achieves ISO 13485 Certification

Related Posts
Total
0
Share